Overview
CJC-1295 and Ipamorelin are two of the most extensively studied synthetic peptides in growth hormone (GH) axis research. Despite both operating in the GH-axis research space, they function through fundamentally different molecular mechanisms — CJC-1295 via GHRH receptor (GHRHR) activation and Ipamorelin via ghrelin receptor (GHSR) activation. This mechanistic difference is precisely why they are frequently studied together in research protocols: their complementary pathways produce synergistic GH responses in animal models that neither compound alone can generate.
Both CJC-1295 and Ipamorelin are unregistered research compounds in Canada and are not approved for human therapeutic use. This comparison is provided for educational and research context purposes only.
CJC-1295 Profile
CJC-1295 is a synthetic 29-amino acid GHRH analogue with four amino acid substitutions that improve resistance to dipeptidyl peptidase IV (DPP-IV) enzymatic degradation. It is most commonly encountered in two formulations:
- CJC-1295 with DAC (Drug Affinity Complex): Half-life of 6–8 days due to albumin binding via maleimide conjugation; produces sustained GH elevation
- CJC-1295 without DAC (Mod-GRF 1-29): Half-life of approximately 30 minutes; produces more pulsatile GH release patterns
For a complete overview of CJC-1295, see What Is CJC-1295?
Ipamorelin Profile
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk. Its defining research characteristic is selectivity: in published animal studies, it produces potent GH release with minimal concurrent stimulation of ACTH and cortisol — in contrast to earlier GHS compounds like GHRP-6 and GHRP-2 which produced more pronounced secondary hormone responses.
For a complete overview of Ipamorelin, see What Is Ipamorelin?
CJC-1295 vs Ipamorelin: Side-by-Side Comparison
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Compound Class | GHRH analogue | GH secretagogue (GHS) |
| Primary Amino Acids | 29 amino acids (based on GHRH(1-29)) | 5 amino acids (pentapeptide) |
| Receptor Target | GHRH receptor (GHRHR) | Ghrelin receptor (GHSR) |
| Half-life (With DAC) | 6–8 days (albumin-bound) | N/A (pentapeptide, ~30 min baseline) |
| Half-life (No DAC) | ~30 minutes | ~30 minutes |
| GH Release Pattern | Sustained elevation (DAC); pulsatile (no DAC) | Pulsatile, GH pulse amplitude amplification |
| ACTH/Cortisol Response | No (different pathway) | Minimal in animal studies (key selectivity feature) |
| Mechanism | Pituitary somatotroph stimulation via GHRHR | GHSR activation; may reduce somatostatin tone |
| Molecular Origin | ConjuChem (synthetic GHRH analogue) | Novo Nordisk (synthetic GHS peptide) |
| Approved Status (Canada) | Not approved — research compound only | Not approved — research compound only |
Receptor Pathways and Mechanisms
Understanding the mechanistic differences between CJC-1295 and Ipamorelin is essential for understanding why they are studied together:
CJC-1295: GHRHR Pathway
CJC-1295 activates the GHRH receptor on pituitary somatotroph cells. This triggers:
- Adenylyl cyclase activation → increased intracellular cAMP
- GH synthesis and secretion via somatotroph cells
- Sustained or pulsatile pattern depending on DAC formulation
Ipamorelin: GHSR Pathway
Ipamorelin activates the ghrelin receptor (GHSR) on somatotrophs and other hypothalamic neurons. This triggers:
- Phospholipase C signalling → intracellular calcium mobilization
- GH secretion from somatotrophs
- Potential somatostatin suppression (reducing GH-inhibitory tone)
- Minimal concurrent ACTH/cortisol stimulation (key selectivity feature)
Why They Synergize
Because CJC-1295 (GHRHR) and Ipamorelin (GHSR) activate distinct receptor pathways that converge on GH secretion, simultaneous administration in animal research produces synergistic GH responses. The two pathways appear to engage complementary intracellular signalling cascades in somatotrophs, resulting in greater GH release than either compound alone.
Synergistic Research Applications
The primary research rationale for studying CJC-1295 and Ipamorelin together is their synergistic effect on GH release. Published animal research has documented:
- Additive/synergistic GH responses: Combined administration produces greater GH elevation than predicted by additive effects of each compound
- Complementary mechanisms: GHRH pathway (synthesis stimulation) + GHSR pathway (pulse amplitude + somatostatin suppression) = optimized GH response
- Research model versatility: Allows researchers to design protocols examining sustained GH elevation (CJC-1295 DAC) combined with enhanced pulsatility (Ipamorelin)
This synergistic approach is particularly relevant to research examining GH axis dynamics, IGF-1 responses, and body composition endpoints in animal models. However, no synergistic effect from combined administration has been established in humans.
GH Response Profiles in Animal Models
Published preclinical research demonstrates distinct GH response profiles for each compound:
CJC-1295 GH Response
- CJC-1295 DAC: Mean GH increases of 2–10 fold above baseline; sustained elevation over days after single administration in rodents and non-human primates
- CJC-1295 no DAC: More pulsatile profile; peaks within minutes of administration, rapidly returns to baseline
Ipamorelin GH Response
- Potent GH release: Produces significant increases in GH secretion in animal models
- Pulsatile pattern: Amplitude-enhancing effect on GH pulses
- Minimal ACTH/cortisol: Key selectivity feature distinguishing Ipamorelin from earlier GHS compounds
Combined Protocol Response
When CJC-1295 and Ipamorelin are combined in animal research protocols, documented GH responses often exceed the predicted additive effect, supporting a synergistic mechanism.
Research Context in Canada
Neither CJC-1295 nor Ipamorelin is approved by Health Canada for any human therapeutic use. Both are classified as research compounds in Canada and are available for in-vitro and laboratory research purposes only. Researchers in Canada conducting research with these compounds must operate within applicable regulatory and ethics frameworks, including:
- Institutional Research Ethics Board (REB) approval for any animal or human research
- Compliance with animal care and use guidelines
- Adherence to Health Canada’s regulatory framework for research compounds
For broader compliance context, see research compound safety and compliance in Canada and research peptides in Canada.
Storage and Handling
Both CJC-1295 and Ipamorelin require proper cold-chain storage for research-grade integrity:
CJC-1295 Storage
- Long-term (lyophilized): −20°C or below
- Short-term: 2–8°C for limited periods
- Post-reconstitution: 2–8°C; avoid repeated freeze-thaw
Ipamorelin Storage
- Long-term (lyophilized): −20°C or below
- Short-term: 2–8°C for limited periods
- Post-reconstitution: 2–8°C; avoid repeated freeze-thaw
See peptide storage guide and peptide reconstitution guide for detailed protocols.
Frequently Asked Questions
Q: What is the key difference between CJC-1295 and Ipamorelin?
CJC-1295: GHRH analogue, GHRHR pathway, drives GH synthesis. Ipamorelin: GH secretagogue, GHSR pathway, amplifies GH pulses. Complementary mechanisms = synergistic GH responses in animal models.
Q: Why are CJC-1295 and Ipamorelin studied together?
Because their distinct pathways produce synergistic GH responses in animal research. CJC-1295 (especially DAC form) creates sustained GH elevation; Ipamorelin amplifies pulse amplitude and suppresses somatostatin. Together they engage complementary intracellular signalling, producing greater GH elevation than either alone.
Q: What is DAC and why does it matter?
DAC (Drug Affinity Complex): maleimide-reactive bioconjugation element allowing CJC-1295 to bind serum albumin, extending half-life to 6–8 days. DAC form = sustained GH elevation; non-DAC (Mod-GRF) = ~30 min half-life, pulsatile GH. Choose based on research design goals.
Q: Are CJC-1295 and Ipamorelin approved for human use in Canada?
No. Neither is approved by Health Canada. Both are research compounds for in-vitro and laboratory use only.
Q: What published research exists comparing these compounds?
Animal research documents synergistic GH responses when combined. CJC-1295 DAC: 2–10 fold baseline elevation sustained over days. Ipamorelin: pulsatile amplitude enhancement, minimal ACTH/cortisol. Direct comparison studies limited but support mechanistic complementarity.
Related Articles
- What Is CJC-1295? Research Overview
- What Is Ipamorelin? Research Overview
- What Is Tesamorelin? Research Overview
- Tesamorelin vs HGH: Research Comparison
- Peptides for Metabolic Research
- Peptides for Longevity Research
Disclaimer: All compounds discussed on this page are intended strictly for laboratory and research purposes. They are not approved for human use, are not intended to diagnose, treat, cure, or prevent any disease or condition, and should not be used outside of a controlled research environment. TrueCanPeptides does not provide medical advice. Consult a qualified healthcare professional before making any health-related decisions. Research compounds are sold for in-vitro and laboratory use only.
See also: What is Ipamorelin?
See also: What is CJC-1295?